Funded project

Brest cancer Research

Breast cancer is one of the most common tumors and is one of the leading causes of cancer death in women, especially in developed countries.

Funded thanks to:
  • Donors
  • Total raised
    • clients 2.750€
  • Direct beneficiaries 30

    Those people who have naturally benefited from the project's interventions.

  • Indirect beneficiaries 100

    Those identifiable people who will potentially recieve an effect from the project's activities.

CRIS Cancer


  • Staff 2.750€
  • Total 2.750€


Breast cancer is the most frequent type of cancer in women. It is estimated that one in 10 women may suffer from it sometime during their life. Although a large majority of breast cancer tumours are cured, even today 20% of patients are not. Resistance to treatment or the absence of specific therapies against certain types of breast cancer explains why certain tumours cannot be completely eliminated.

The breast cancer research projects headed by Atanasio Pandiella and Alberto Ocaña are focused mainly on two particularly aggressive types of breast cancer:

  • Triple -Negative Breast Tumours: Triple -negative breast cancer receives this name because the tumour cells lack certain molecules that define other types of breast cancer. These tumours have a very poor prognosis, and there is currently no specific therapy against them. Research in this field is therefore urgently required to develop effective therapies against these types of tumours.
  • Her2+ Breast Tumours: Her2+ breast cancers are very aggressive tumours, with cells presenting a large amount of the protein called Her2, which is the main reason for their transformation. Although there is a treatment against this type of tumours, a large number of patients develop a resistance to the treatments. This project is focused on finding out the mechanisms whereby the tumour cells avoid the treatment.

Project objectives

Identify the causes associated to resistance of certain treatments and develop new drugs to improve the prognosis and cure rate.


  • Generation of in vitro and in vivo models resistance anti-HER2 therapies. It is creating cells resistant to trastuzumab and lapatinib proposed by continued treatment with these drugs.
  • Detailed analysis of the mechanisms responsible for this resistance analysis using genomic and proteomic techniques.
  • Conducting screenings RNAi libraries and inhibitory compounds, with the aim of identifying targets that could be used to combat resistance mechanisms.

Who will benefit?

Improve four patients will have their DNA alterations analyzed.

Updates & Links

This website uses cookies. If you continue browsing we will consider you have accepted their use . Obtain more information.

Are you an eCommerce? Allow your clients make donations. INSTALL WORLDCOO